Branched DNA (bDNA) Technology for Direct Quantification of Nucleic Acids: Research and Clinical Applications

  • Janice A. Kolberg
  • Douglas N. Ludtke
  • Lu-Ping Shen
  • Will Cao
  • Darrah O’Conner
  • Mickey S. Urdea
  • Linda J. Wuestehube
  • Marcia E. Lewis
Part of the Advanced Biomedical Technologies book series (ABT)

Abstract

Over the past decade a number of new technologies, including the polymerase chain reaction (PCR) (Mullis and Faloona, 1987), have emerged for the detection and quantification of nucleic acid molecules. Distinct among these is the branched DNA (bDNA) assay which, unlike its target amplification counterparts, uses a signal amplification scheme to enhance detection of physiologic concentrations of target nucleic acids. The basis of the bDNA assay involves the specific hybridization of bDNA and enzymelabeled oligonucleotide probes to target nucleic acids; this is described in detail in the accompanying chapter in this book, entitled “Branched DNA Technology for Direct Quantification of Nucleic Acids: Design and Performance.” The bDNA assay is inherently quantitative and nonradioactive, and has proven to be a reproducible and accurate means of quantifying nucleic acid molecules. The bDNA assay offers several advantages for research and clinical applications; it:
  • provides direct quantification of nucleic acid molecules at physiological levels. Since bDNA assays do not require highly purified nucleic acid preparations, inhibitors of enzyme-dependent amplification techniques are of no concern.

  • allows a wide diversity of specimen types to be used.

  • can be used with reference standards to ensure accuracy for applications requiring absolute quantification, or without standards for applications requiring only assessment of relative changes in nucleic acid concentrations.

  • exhibits a high level of sensitivity (moderately expressed genes can be detected using as few as 50–100 cells). The level of sensitivity can be modulated by altering the number of target-specific extenders to accommodate specific applications.

  • is thoroughly tested for within-lot and between-lot precision to ensure reproducibility (2.2- to 3-fold changes can be discerned as statistically significant).

Keywords

Toxicity Hepatitis Lymphoma Codon Interferon 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bartlett JD, Luethy JD, Carlson SG, Sollott SJ, and Holbrook NJ (1992): Calcium ionophore A23187 induces expression of the growth arrest and DNA damage inducible CCAAT/enhancer-binding protein (C/EBP)- related gene, gaddl53. Ca2+ increases transcriptional activity and mRNA stability. J Biol Chem 267:20465–70.PubMedGoogle Scholar
  2. Biragyn A, Arkins S, and Kelley KW (1994): Riboprobe expression cassettes for measuring IGF-I, beta-actin and glyceraldehyde 3-phosphate dehydrogenase transcripts. J Immunol Meth 168:235–44.CrossRefGoogle Scholar
  3. Cao Y, Ho DD, Todd J, Kokka R, Urdea M, Lifson JD, Piatak M, Jr., Chen S, Hahn BH, Saag MS, and Shaw GM (1995): Clinical evaluation of branched DNA (bDNA) signal amplification for quantifying HIV-1 in human plasma. AIDS Res Hum Retroviruses 11:353–61PubMedCrossRefGoogle Scholar
  4. Cao WW, Landay AL, Shen L-P, Siegel J, DePaz N, and Kolberg J: Quantitative analysis of cytokine expression in peripheral blood mononuclear cells from HIV-infected individuals (in preparation).Google Scholar
  5. Chernoff DN, Hoo BS, Shen L-P, Kelso RJ, Kolberg JA, Drew WL, Miner RC, Lalezari JP, and Urdea MS: Quantification of CMV DNA in peripheral blood leukocytes using a branched DNA (bDNA) signal amplification assay (submitted).Google Scholar
  6. Crawford DR, Schools GP, and Davies KJ (1996): Oxidant-inducible adapt 15 RNA is associated with growth arrest- and DNA damage-inducible gaddl53 and gadd45. Arch Biochem Biophys 329:137–44.PubMedCrossRefGoogle Scholar
  7. Davis GL, Lau JY, Urdea MS, Neuwald PD, Wilber JC, Lindsay K, Perrillo RP, and Albrecht J (1994): Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 19:1337–41.PubMedCrossRefGoogle Scholar
  8. Deschamps J, Meijlink F, and Verma IM (1985): Identification of a trancriptional enhancer element upstream from the proto-oncogene fos. Science 230:1174–7.PubMedCrossRefGoogle Scholar
  9. Eastman PS, Urdea M, Besemer D, Stempien M, and Kolberg J (1995): Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations. J Acquir Immune Defic Syndr Hum Retrovirol 9:264–73.PubMedGoogle Scholar
  10. Fischbach M, Sabbioni E, and Bromley P (1993): Induction of the human growth hormone gene placed under human hsp70 promoter control in mouse cells: a quantitative indicator of metal toxicity. Cell Biol Toxicol 9:177–88.PubMedCrossRefGoogle Scholar
  11. Flood J, Drew WL, Miner R, Jekic-McMullen D, Shen L-P, Kolberg J, Garvey J, Follansbee S, and Poscher M: Detection of cytomegalovirus (CMV) polyradiculopathy and documentation of in vivo anti-CMV activity in cerebrospinal fluid using branched DNA signal amplification and CMV antigen assays (submitted).Google Scholar
  12. Hendricks DA, Stowe BS, Hoo BS, Kolberg J, Irvine BS, Neuwald PD, Urdea MS, and Perillo RP (1995): Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Am J Clin Pathol 104:537–46.PubMedGoogle Scholar
  13. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M (1995): Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123–6.PubMedCrossRefGoogle Scholar
  14. Hollander MC and Fornance AJ (1989): Induction of fos RNA by DNA-damaging agents. Cancer Res 49:1687–92.PubMedGoogle Scholar
  15. Hosotsubo H et al. (1994): Quantitation of serum HBV DNA by branched DNA probe assay with chemiluminescence detection. Med Pharm 31:743–51.Google Scholar
  16. Kapke GF, Watson G, Sheffler S, Hunt D, and Frederick C: Comparison of the Chiron Quantiplex branched DNA (bDNA) assay and the Abbott Genostics solution hybridization assay for quantification of hepatitis B viral DNA. J Virol Hepatitis (in press).Google Scholar
  17. Kern D, Collins M, Fultz T, Detmer J, Hamren S, Peterkin JJ, Sheridan P, Urdea M, White R, Yeghiazurian T, and Todd J (1996): An enhanced sensitivity branched DNA assay for the quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 34:3196–202.PubMedGoogle Scholar
  18. Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC, and Jaffe HS (1995): (S)-l-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 171:788–96.PubMedCrossRefGoogle Scholar
  19. Lau JYN, Mizokami M, Ohno T, Diamond DA, Kniffen J, and Davis GL (1993): Discrepancy between biochemical and virological responses to interferon-a in chronic hepatitis C. Lancet 342:1208–9.PubMedCrossRefGoogle Scholar
  20. Lin HJ, Myers LE, Yen LB, Hollinger FB, Henrard D, Hooper CJ, Kokka R, Kwok S, Rasheed S, Vahey M, Winters MA, McQuay LJ, Nara PL, Reichelderfer P, Coombs RW, and Jackson JB (1994): Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 170:553–62.PubMedCrossRefGoogle Scholar
  21. MacGregor JT, Farr S, Tucker JD, Heddle JA, Tice RR, and Turteltaub KW (1995): New molecular endpoints and methods for routine toxicit testing. Fundamental Appl Toxicol 26:156–73.CrossRefGoogle Scholar
  22. Mellors JW, Rinaldo CRJ, Gupta P, White RM, Todd JA, and Kingsley LA (1996): Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167–70.PubMedCrossRefGoogle Scholar
  23. Mullis KB and Faloona FA (1987): Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Meth Enzymol 155:335–50.PubMedCrossRefGoogle Scholar
  24. Orito E, Mizokami M, Suzuki K, Ohba K, Ohno T, Mori M, Hayashi K, Kato K, Iino S, and Lau JYN (1995): Loss of serum HCV RNA at week 4 of interferon-a therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 46:109–15.PubMedCrossRefGoogle Scholar
  25. Perelson AS, Neuman AU, Markowitz M, Leonard JM, and Ho DD (1996): HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582–6.PubMedCrossRefGoogle Scholar
  26. Shen L-P, Sheridan P, Cao W, Dailey PJ, Urdea MS, and Kolberg J: Quantification of cytokine mRNA in peripheral blood mononuclear cells using branched DNA (bDNA) technology (in preparation).Google Scholar
  27. Terrault N, Wilber J, and Feinman SV (1994): Response to interferon therapy predicted by changes in serum HCV-RNA titer early in treatment. In Program and Abstracts of the Digestive Diseases Meeting, New Orleans, LA.Google Scholar
  28. Todd J, Pachl C, White R, Yeghiazarian T, Johnson P, Taylor B, Holodniy M, Kern D, Hamren S, Chernoff D, and Urdea M (1995): Performance characteristics for the quantitation of plasma HIV-1 RNA using branched DNA signal amplification technology. J Acquir Immune Defic Syndr Hum Retrovirol 10 (supplement 2):S35-S44.PubMedGoogle Scholar
  29. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kiriyama S, Orito E, and Mizokami M (1996): Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alpha therapy in chronic hepatitis C patients. J Med Virol 48:354–9.PubMedCrossRefGoogle Scholar
  30. Wang J, Shen L-P, Najafi H, Kolberg JA, Matschinsky FM, Urdea M, and German M (1997): Regulation of insulin preRNA splicing by glucose. Proc Natl Acad Sci USA (in press).Google Scholar
  31. Watanabe Y, Hino K et al. (1993): Detection of HBV DNA by bDNA probe assay and evaluation of its clinical utility. Med Pharm 30:1217–26.Google Scholar
  32. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, and Shaw GM (1995): Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117–26.PubMedCrossRefGoogle Scholar
  33. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, Shin S, Tanno M, Urdea MS, and Kolberg JA (1995): Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 22:1351–4.PubMedGoogle Scholar
  34. Zaaijer HL, ter Borg F, Cuypers HTM, Hermus MCAH, and Lelie PN (1994): Comparison of methods for detection of hepatitis B virus DNA. J Clin Microbiol 32:2088–91.PubMedGoogle Scholar
  35. Zhao J, Araki N, and Nishimoto SK (1995): Quantitation of matrix Gla protein mRNA by competitive polymerase chain reaction using glyceraldehyde-3-phosphate dehydrogenase as an internal control. Gene 155:159–65.PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1998

Authors and Affiliations

  • Janice A. Kolberg
    • 1
  • Douglas N. Ludtke
  • Lu-Ping Shen
    • 1
  • Will Cao
  • Darrah O’Conner
  • Mickey S. Urdea
    • 1
  • Linda J. Wuestehube
    • 1
  • Marcia E. Lewis
    • 1
  1. 1.Chiron CorporationEmeryvilleUSA

Personalised recommendations